Evaluating the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors

Cancer Clinical Trial

Official title:

An Open-Label, Phase I Study to Evaluate the Pharmacokinetics and Tolerance of Co-administration of Oral Multiple Dose of Ketoconazole and an IV (Bolus) Infusion of Eribulin in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01000376
• Other study ID #: E7389-E044-109
• Status: Completed
• Phase: Phase 1
• First received: October 22, 2009
• Last updated: September 19, 2013
• Start date: February 2009
• Est. completion date: September 2009

Study information

• Verified date: September 2013
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: The Netherlands: Centrale Commissie Mensgebonden Onderzoek (CCMO)
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate whether ketoconazole, taken orally, influences the level of eribulin in the blood when the two drugs are given at the same time. The study will enroll patients with solid tumors whose cancer became worse even after standard treatment, or for whom there is no standard treatment available. The study will also investigate whether eribulin given together with ketoconazole is safe (has few side-effects) and is effective against cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: September 2009
• Est. primary completion date: August 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have a histologically or cytologically confirmed advanced solid tumor that has progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy).

2. Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy = Grade 2 and alopecia.

3. Patients must be aged = 18 years.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

5. Life expectancy of = 3 months.

6. Patients must have adequate renal function as evidenced by serum creatinine = 2.0 mg/dL (= 176 mol/L) or calculated creatinine clearance = 40 mL/minute (min) per the Cockcroft and Gault formula.

7. Patients must have adequate hepatic function as evidenced by bilirubin = 1.5 times the upper limit of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) = 3 times the ULN, (in the case of liver metastases = 5 times ULN or in the case of bone metastases, the liver specific alkaline phosphatase = 3 times ULN).

8. Patients must have adequate bone marrow function as evidenced by absolute neutrophil count (ANC) = 1.5 x 10^9/L, hemoglobin = 10.0 g/dL or = 6.2 mmol/L (a hemoglobin < 10.0 g/dL or < 6.2 mmol/L is acceptable if it is corrected by growth factor or transfusion), and platelets = 100 x 10^9/L.

9. Patients must be willing and able to comply with the study protocol for the duration of the study.

10. Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

Exclusion Criteria:

1. Patients who have received any of the following treatments within the specified period before eribulin treatment starts:

1. Chemotherapy, radiation or biological therapy within 2 weeks.

2. Hormonal therapy within 1 week.

3. Any investigational drug within 4 weeks.

2. Patients who are receiving anti-coagulant therapy with warfarin or related compounds, other than for line patency and cannot be changed to heparin-based therapy, are not eligible. If a patient is to continue on mini-dose warfarin, then the prothrombin time (PT) or international normalized ratio (INR) must be closely monitored.

3. Patients receiving, at the time the study starts, any medication, dietary supplements or other compounds or substances known to induce or inhibit CYP3A4 activity, with the exception of ketoconazole. A comprehensive list can be found at http://medicine/iupui.edu/flockhart/table.htm.

4. Patients for whom the use of ketoconazole is contraindicated.

5. Patients who are receiving drugs that might influence ketoconazole metabolism.

6. Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.

7. Fertile men who are not willing to use contraception or fertile men with a female partner who is not willing to use contraception.

8. Patients whose intestinal absorption is impaired.

9. Severe/uncontrolled intercurrent illness/infection.

10. Significant cardiovascular impairment (history of congestive heart failure > New York Heart Association (NYHA) Grade II, unstable angina or myocardial infarction within the past 6 months, or serious cardiac arrhythmia.

11. Patients with organ allografts requiring immunosuppression (not including blood and blood components transfusions).

12. Patients with known positive human immunodeficiency virus (HIV) status.

13. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment with eribulin.

14. Patients with meningeal carcinomatosis.

15. Patients with a hypersensitivity to halichondrin B and/or halichondrin B-like compounds.

16. Patients with pre-existing neuropathy > Grade 2.

17. Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Cancer

Intervention

Drug:
• Eribulin alone
Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m^2 alone on Day 1, then eribulin IV 0.7 mg/m^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days.
• Eribulin plus Ketoconazole
Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days.

Locations

Country	Name	City	State
Netherlands	The Netherlands Cancer Institute	Amsterdam	Noord-Holland

Sponsors (1)

Lead Sponsor	Collaborator
Eisai Limited

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean (SD) Maximum Observed Concentration (Cmax) of Eribulin		7 days after dosing on Days 1 and 15	No
Primary	Mean (SD) Area Under Concentration Time Curve From Zero to Infinity (AUC 0-oo) of Eribulin		7 days after dosing on Days 1 and 15	No
Secondary	Safety of Eribulin Administered Alone or Coadministered With Oral Ketoconazole, as Measured by Number of Subjects With Adverse Events.		monitored throughout	Yes